Search results for "Inhalation"

showing 10 items of 326 documents

Noninvasive Ventilation and Outcomes Among Immunocompromised Patients

2016

03 medical and health sciencesOxygen inhalation therapymedicine.medical_specialty0302 clinical medicine030228 respiratory systembusiness.industryMedicineNoninvasive ventilation030212 general & internal medicineGeneral MedicinebusinessIntensive care medicineJAMA
researchProduct

Molecular similarities and differences from human pulmonary fibrosis and corresponding mouse model: MALDI imaging mass spectrometry in comparative me…

2017

Animal models can reproduce some model-specific aspects of human diseases, but some animal models translate poorly or fail to translate to the corresponding human disease. Here, we develop a strategy to systematically compare human and mouse tissues, and conduct a proof-of-concept experiment to identify molecular similarities and differences using patients with idiopathic pulmonary fibrosis and a bleomycin-induced fibrosis mouse model. Our novel approach employs high-throughput tissue microarrays (TMAs) of humans and mice, high-resolution matrix-assisted laser desorption/ionization-Fourier transform-ion cyclotron resonance-mass spectrometry imaging (MALDI-FT-ICR-MSI) to spatially resolve ma…

0301 basic medicineMALDI imagingPulmonary FibrosisSecondary MetabolismComputational biologyBiologyBioinformaticsProof of Concept StudyPathology and Forensic MedicineBleomycinMice03 medical and health sciencesIdiopathic pulmonary fibrosisMetabolomicsSpecies SpecificityFibrosisAdministration InhalationSpectroscopy Fourier Transform InfraredPulmonary fibrosismedicineAnimalsCluster AnalysisHumansMetabolomicsLungPhysiology ComparativeMolecular BiologyAntibiotics AntineoplasticTissue microarrayCell BiologyCyclotronsmedicine.diseaseImmunohistochemistryDisease Models AnimalMatrix-assisted laser desorption/ionization030104 developmental biologyTissue Array AnalysisSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunohistochemistryLaboratory Investigation
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct

Release of copper-amended particles from micronized copper-pressure-treated wood during mechanical abrasion

2016

Background We investigated the particles released due to abrasion of wood surfaces pressure-treated with micronized copper azole (MCA) wood preservative and we gathered preliminary data on its in vitro cytotoxicity for lung cells. The data were compared with particles released after abrasion of untreated, water (0% MCA)-pressure-treated, chromated copper (CC)-pressure-treated wood, and varnished wood. Size, morphology, and composition of the released particles were analyzed. Results Our results indicate that the abrasion of MCA-pressure-treated wood does not cause an additional release of nanoparticles from the unreacted copper (Cu) carbonate nanoparticles from of the MCA formulation. Howev…

0301 basic medicinePreservativeCopper particlesAbrasion (mechanical)Cell SurvivalCytotoxicityIn vitro cytotoxicityBiomedical EngineeringNanoparticlechemistry.chemical_elementMedicine (miscellaneous)Pharmaceutical ScienceBioengineering010501 environmental sciences01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryCell LineExposure03 medical and health sciencesPressureHumansCytotoxicity0105 earth and related environmental sciencesChemistryResearchtechnology industry and agricultureWaterCytotoxicity; Copper particles; Debris; Exposure; Inhalation; Wood dustMechanical abrasionCopperWood030104 developmental biologyInhalationA549 CellsMolecular MedicineNanoparticlesComposition (visual arts)DebrisReactive Oxygen SpeciesCopperWood dustNuclear chemistry
researchProduct

Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections.

2017

The influence of vitamin D3 and its metabolites calcifediol (25(OH)D) and calcitriol on immune regulation and inflammation is well described, and raises the question of potential benefit against bacterial infections. In the current study, 25(OH)D was encapsulated in liposomes to enable aerosolisation, and tested for the ability to prevent pulmonary infection by Pseudomonas aeruginosa. Prepared 25(OH)D-loaded liposomes were nanosized and monodisperse, with a negative surface charge and a 25(OH)D entrapment efficiency of approximately 23%. Jet nebulisation of liposomes was seen to yield an aerosol suitable for tracheo-bronchial deposition. Interestingly, 25(OH)D in either liposomes or ethanol…

0301 basic medicineVitaminRMCalcitriolCystic FibrosisPharmaceutical ScienceInflammationBronchiBiologyPharmacologymedicine.disease_causeMicrobiologyProinflammatory cytokineCell Line03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinePseudomonas infectionAdministration InhalationmedicineAnimalsHumansImmunologic FactorsPseudomonas InfectionsRespiratory Tract InfectionsCalcifediolLiposomePseudomonas aeruginosaEpithelial CellsGeneral Medicinemedicine.disease030104 developmental biology030228 respiratory systemchemistryLiposomesPseudomonas aeruginosaCytokinesNanoparticlesCalcifediolmedicine.symptomBiotechnologymedicine.drug
researchProduct

AFM study of interaction forces in supported planar DPPC bilayers in the presence of general anesthetic halothane

2006

International audience; In spite of numerous investigations, the molecular mechanism of general anesthetics action is still not well understood. It has been shown that the anesthetic potency is related to the ability of an anesthetic to partition into the membrane. We have investigated changes in structure, dynamics and forces of interaction in supported dipalmitoylphosphatidylcholine (DPPC) bilayers in the presence of the general anesthetic halothane. In the present study, we measured the forces of interaction between the probe and the bilayer using an atomic force microscope. The changes in force curves as a function of anesthetic incorporation were analyzed. Force measurements were in go…

12-DipalmitoylphosphatidylcholineMicrodomainsKineticsLipid BilayersBiophysics02 engineering and technology010402 general chemistryMicroscopy Atomic Force01 natural sciencesBiochemistrychemistry.chemical_compoundPlanar bilayermedicineLipid bilayerChemistryBilayerForce spectroscopyCell Biology021001 nanoscience & nanotechnologyForce spectroscopy0104 chemical sciencesCrystallographyKineticsMembrane[ PHYS.PHYS.PHYS-AO-PH ] Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph]Chemical physicsDipalmitoylphosphatidylcholineAnestheticAnesthetics InhalationHalothane0210 nano-technologyHalothanemedicine.drugBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

2019

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial…

3003AgonistDrugAlginatesCell Survivalmedicine.drug_classmedia_common.quotation_subjectSodium alginate polymerPharmaceutical ScienceChronic obstructive pulmonary disease (COPD)Inflammation02 engineering and technologyPharmacology030226 pharmacology & pharmacyCell LinePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinecAMPmedicineHumansAerodynamic diameterAdrenergic beta-2 Receptor AgonistsSalmeterol Xinafoatemedia_commonDrug CarriersCOPDInhalationChemistryTherapeutic effectAdhesiveness021001 nanoscience & nanotechnologymedicine.diseaseLipidsSALMETEROL XINAFOATEBronchodilator Agentsrespiratory tract diseasesSalmeterol Xinafoate (SX)MucusAerodynamic diametermedicine.symptom0210 nano-technologyInternational Journal of Pharmaceutics
researchProduct

An inhaled tumor necrosis factor-alpha-derived TIP peptide improves the pulmonary function in experimental lung injury: inhaled TIP peptide in experi…

2012

INTRODUCTION The lectin-like domain of TNF-α enhances the fluid clearance across the alveolar barrier. For experimental purposes, the lectin-like domain can be mimicked by a synthetic peptide representing the TIP-motif of TNF-α. The present study aims to assess the acute effect of TIP on the pulmonary function in a porcine model of acute respiratory distress syndrome (ARDS). METHODS Lung injury was induced in 16 pigs (25-27 kg) by bronchoalveolar lavage followed by injurious ventilation. Following randomisation, either nebulised TIP (1 mg/kg; AP301, APEPTICO, Vienna, Austria) or water for injection (control group) was administered. During 5 h of monitoring, the extravascular lung water inde…

ARDSmedicine.diagnostic_testInhalationbusiness.industryGeneral MedicineLung injurymedicine.diseasePlaceboPulmonary function testingAnesthesiology and Pain MedicineBronchoalveolar lavageAnesthesiamedicineBreathingPulmonary shuntmedicine.symptombusiness
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

TH17 cells mediate pulmonary collateral priming

2010

Background Our laboratory has shown that inhalational sensitization to new antigens is facilitated through an ongoing T H 2-polarized inflammation of the lung, a phenomenon we call "collateral priming." Objective We were interested to analyze whether a T H 1-polarized pulmonary inflammation also facilitates priming toward new antigens and which cytokine or cytokines are involved. Methods T H 1-polarized T cells were generated in vitro and transferred into congenic mice. Mice were challenged initially with cognate antigen and an unrelated antigen; consecutively, they received cognate antigen or the secondary antigen. Airway inflammation, antigen-specific IgG2a levels, and airway hyperrespons…

Adoptive cell transfermedicine.medical_treatmentImmunologyPriming (immunology)Mice TransgenicCell SeparationLymphocyte ActivationArticleAllergic sensitizationMiceAntigenmedicineAnimalsImmunology and AllergyCytotoxic T cellAntigen-presenting cellLungMice Inbred BALB Cbusiness.industryInterleukin-17PneumoniaFlow CytometryAdoptive TransferCytokineInhalationImmunologyTh17 CellsInterleukin 17Bronchial HyperreactivitybusinessJournal of Allergy and Clinical Immunology
researchProduct